Topical cannabidiol composition and method for relieving symptoms associated with rheumatoid arthritis

Abstract

A topical composition and method for relieving one or more symptoms associated with rheumatoid arthritis are disclosed. The composition comprises cannabidiol, a carrier system comprising coconut oil, beeswax, and cocoa butter, and menthol. The composition is formulated as a semisolid topical preparation for application to skin over affected joints or areas of inflammation. The carrier system provides a dermal carrier phase that supports localised application and retention of the composition at the site of use, while menthol may assist delivery of cannabidiol to local tissues. In use, the composition is topically applied to relieve symptoms associated with rheumatoid arthritis, including pain, stiffness, swelling, tenderness, and impaired mobility. The composition may optionally be formulated as a salve, including a roll -on salve, and may further comprise one or more essential oils or botanical extracts.

Description

Topical Cannabidiol Composition and Method for Relieving Symptoms Associated with Rheumatoid Arthritis Field of the Invention

[0001] The present disclosure relates to topical pharmaceutical and therapeutic compositions and methods for relieving one or more symptoms associated with rheumatoid arthritis. More particularly, the disclosure relates to topical compositions comprising cannabidiol and a semisolid carrier system for local application to affected joints or areas of inflammation.Background of the Invention

[0002] Rheumatoid arthritis is a chronic autoimmune disorder characterised by inflammation and progressive damage to synovial joints, resulting in pain, swelling, stiffness, and reduced mobility. The condition affects millions of individuals worldwide and is a leading cause of disability, significantly impairing the quality of life. Current treatment strategies primarily rely on systemic medications such as diseasemodifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and opioids. While these treatments can provide relief, their effectiveness is limited for many patients, and they are often associated with significant side effects, including gastrointestinal, cardiovascular, and immunosuppressive complications.

[0003] Moreover, systemic treatments do not always target localised symptoms effectively, leaving patients with residual pain and inflammation in specific joints or areas. Topical treatments offer the advantage of direct application to affected areas, minimising systemic exposure and associated side effects. However, conventional topical therapies, such as corticosteroid creams and NSAID gels, often fail to achieve adequate penetration through the skin’s barrier, limiting their therapeutic efficacy.

[0004] As a result, there is a pressing need for a safe, effective, and non-invasive treatment option that can provide targeted relief for the symptoms of rheumatoid arthritis, improve mobility, and reduce dependence on systemic medications.Summary of the Disclosure

[0005] According to one aspect, the present disclosure provides a topical composition for relieving one or more symptoms associated with rheumatoid arthritis, the composition comprising cannabidiol (CBD) or an isolate thereof as the active ingredient, a carrier system comprising coconut oil, beeswax, and cocoa butter, and menthol, wherein the composition is formulated to enhance dermal absorption and bioavailability of cannabidiol in local tissues affected by rheumatoid arthritis.

[0006] The composition may provide a semisolid topical formulation suited to direct application to skin over or adjacent affected joints or other areas associated with rheumatoid arthritis. The semisolid carrier system may assist in maintaining the cannabidiol at the site of application for a period sufficient to promote dermal uptake and local tissue exposure.

[0007] The carrier system comprising coconut oil, beeswax, and cocoa butter may provide a dermal carrier phase that supports spreading of the composition over the skin surface, adherence of the composition to the applied area, and retention of the active ingredient at the application site. In this way, the composition may facilitate localised delivery of cannabidiol to tissues associated with affected joints.

[0008] The menthol may further contribute to delivery of the cannabidiol through the skin, thereby increasing the availability of cannabidiol in local tissues. The composition may accordingly provide enhanced local bioavailability of cannabidiol at or near the site of pain, inflammation, stiffness, tenderness, or impaired mobility associated with rheumatoid arthritis.

[0009] In use, the composition may be applied directly to affected joints or areas of inflammation to provide localised relief. Such topical application may reduce systemic exposure associated with orally administered or otherwise systemically delivered treatments, while providing a practical, non-invasive, and effective means for managing symptoms associated with rheumatoid arthritis and improving patient comfort and mobility.

[0010] By providing a topical composition comprising cannabidiol as the active ingredient and formulated to enhance dermal absorption and local tissuebioavailability of cannabidiol, the present disclosure may enable targeted relief of one or more symptoms associated with rheumatoid arthritis in a practical, non-invasive manner.

[0011] In an embodiment, the cannabidiol or isolate is present in the composition in a concentration of 30 mg / g to 60 mg / g. In a particular embodiment, the cannabidiol is present in a concentration of about 46 mg / g. Such a concentration may provide an effective amount of the active ingredient for localised topical delivery to tissues associated with affected joints.

[0012] Preferably, the coconut oil is present in a concentration of 8% to 15%, for example about 10.9%, the beeswax is present in a concentration of 25% to 40%, for example about 33%, and the cocoa butter is present in a concentration of 20% to 35%, for example about 27.7%. In this way, the carrier system may provide a dermal carrier phase having a semisolid consistency suited to spreading over the skin surface, adherence to the applied area, and retention of the active ingredient at or near the site of application.

[0013] In an embodiment, the menthol is present in a concentration of 15% to 25%, for example about 21%. The menthol may contribute to dermal delivery of the cannabidiol and may also provide a cooling effect upon application, thereby improving user comfort during topical administration.

[0014] Preferably, the composition further comprises lavender essential oil in a concentration of 0.05% to 0.5%, for example about 0.2%, ginger essential oil in a concentration of 0.05% to 0.5%, for example about 0.2%, and / or arnica extract in a concentration of 0.05% to 0.3%, for example about 0.1%. One or more of these adjunct ingredients may be included to supplement the overall topical character of the composition and to further support local application to affected joints or areas of inflammation.

[0015] In an embodiment, the composition further comprises one or more Tasmanian essential oils. Preferably, the one or more Tasmanian essential oils are selected from Tasmanian Rosalina essential oil, Tasmanian rosemary essential oil, Tasmanian kunzea essential oil, and Tasmanian peppermint essential oil. In particularembodiments, each such essential oil may be present in a concentration of 0.05% to 0.5%, for example about 0.2%. The inclusion of one or more such essential oils may contribute to the topical characteristics of the composition and may provide a desirable adjunct component within the semisolid formulation.

[0016] Preferably, the composition further comprises Tasmanian parsley essential oil in a concentration of 0.05% to 0.5%, for example about 0.2%. In some embodiments, Tasmanian parsley essential oil is included together with one or more of Tasmanian Rosalina essential oil, Tasmanian rosemary essential oil, Tasmanian kunzea essential oil, and Tasmanian peppermint essential oil.

[0017] In an embodiment, the composition further comprises white willow bark extract in a concentration of 0.05% to 0.3%, for example about 0.14%, and / or cayenne extract in a concentration of 0.05% to 0.3%, for example about 0.14%. In some embodiments, these extracts may be incorporated as optional adjuncts in the composition to complement the overall topical formulation.

[0018] Preferably, the composition further comprises calendula extract in a concentration of 0.001% to 0.05%, for example about 0.01%. The calendula extract may provide an additional adjunct component in the composition and may contribute to skin compatibility of the topical preparation.

[0019] In an embodiment, the composition is applied directly to affected joints. For example, the composition may be applied to joints affected by pain, stiffness, swelling, tenderness, or impaired mobility associated with rheumatoid arthritis, thereby enabling localised application at the region of discomfort or inflammation.

[0020] Preferably, the composition is applied to the affected joints at least twice daily. In this manner, repeated topical administration may assist in maintaining local availability of the active ingredient over time.

[0021] In an embodiment, the composition is applied as a roll-on salve. A roll-on salve format may provide a convenient and controlled means of application, assist in delivering the composition directly to a target area, and reduce wastage during use.

[0022] Preferably, the formulation is free of artificial preservatives or synthetic additives. In some embodiments, the absence of artificial preservatives or syntheticadditives may improve suitability of the composition for users seeking a more natural topical preparation or for users having sensitive skin.

[0023] In an embodiment, the disclosure provides a topical composition for relieving one or more symptoms associated with rheumatoid arthritis, the composition comprising cannabidiol or isolate, a carrier system comprising coconut oil, beeswax, and cocoa butter, and menthol, wherein the cannabidiol is present in a concentration of 30 mg / g to 60 mg / g, for example about 46 mg / g, the coconut oil is present in a concentration of 8% to 15%, for example about 10.9%, the beeswax is present in a concentration of 25% to 40%, for example about 33%, the cocoa butter is present in a concentration of 20% to 35%, for example about 27.7%, and the menthol is present in a concentration of 15% to 25%, for example about 21%.

[0024] Preferably, the topical composition further comprises one or more essential oils or extracts selected from lavender essential oil, ginger essential oil, arnica extract, Tasmanian Rosalina essential oil, Tasmanian rosemary essential oil, Tasmanian kunzea essential oil, Tasmanian peppermint essential oil, Tasmanian parsley essential oil, white willow bark extract, cayenne extract, and calendula extract, each being present, where included, within the respective concentration ranges described herein. In this way, the various optional adjunct components may be incorporated individually or in combination to tailor the formulation while maintaining the semisolid topical composition centred on cannabidiol (CBD) isolate as the active ingredient.

[0025] Other aspects of the invention are also disclosed.Description of Embodiments

[0026] There is provided a method of relieving one or more symptoms associated with rheumatoid arthritis through the topical application of a composition formulated for local delivery of cannabidiol to tissues associated with affected joints or other areas of inflammation. The composition may be applied to relieve pain, stiffness, swelling, tenderness, or impaired mobility associated with rheumatoid arthritis. In this way, the composition may provide a practical and non-invasive treatment approach directed to local symptom relief.

[0027] The topical composition comprises cannabidiol or cannabidiol isolate as the active ingredient. In some embodiments, the cannabidiol or cannabidiol isolate is present in a concentration of 30 mg / g to 60 mg / g of the formulation. In a particular embodiment, the cannabidiol or cannabidiol isolate is present in a concentration of about 46 mg / g. Cannabidiol is a non-psychoactive cannabinoid and, when incorporated into the present topical formulation, may provide local therapeutic benefit in tissues associated with rheumatoid arthritis. Where cannabidiol isolate is used, the active ingredient may be provided in a form having consistent potency and composition.

[0028] The formulation further comprises a carrier system including coconut oil, beeswax, and cocoa butter. In some embodiments, coconut oil is present in a concentration of 8% to 15%, for example about 10.9%. Coconut oil may act as a carrier for the cannabidiol and may assist in distributing the active ingredient throughout the formulation and across the skin surface upon application. In some embodiments, beeswax is present in a concentration of 25% to 40%, for example about 33%. Beeswax may contribute to the semisolid structure of the composition, thereby assisting the composition to remain at the application site and providing a consistency suited to controlled topical administration. In some embodiments, cocoa butter is present in a concentration of 20% to 35%, for example about 27.7%. Cocoa butter may assist in providing a smooth and spreadable formulation and may contribute to the dermal carrier phase in a manner that supports retention of the composition on the skin.

[0029] Together, the coconut oil, beeswax, and cocoa butter may define a semisolid dermal carrier system that promotes ease of application, adherence to the applied area, and retention of the active ingredient at or near the site of use. By providing a semisolid carrier phase, the formulation may support localised delivery of cannabidiol to tissues associated with affected joints while also providing a product that is convenient for repeated topical use.

[0030] The composition further comprises menthol, which may be provided in crystal form. In some embodiments, the menthol is present in a concentration of 15% to 25%,for example about 21%. The menthol may contribute to dermal delivery of the cannabidiol and may assist in increasing the availability of cannabidiol in local tissues after application. Menthol may also impart a cooling sensation on the skin, which may provide additional comfort upon application to painful or inflamed areas.

[0031] The formulation may further comprise one or more optional essential oils or extracts. In some embodiments, lavender essential oil is present in a concentration of 0.05% to 0.5%, for example about 0.2%. In some embodiments, ginger essential oil is present in a concentration of 0.05% to 0.5%, for example about 0.2%. In some embodiments, arnica extract is present in a concentration of 0.05% to 0.3%, for example about 0.1%. One or more of these optional adjunct components may be included to complement the overall topical character of the composition.

[0032] In some embodiments, the composition further comprises one or more Tasmanian essential oils. Such essential oils may be selected from Tasmanian Rosalina essential oil, Tasmanian rosemary essential oil, Tasmanian kunzea essential oil, Tasmanian peppermint essential oil, and Tasmanian parsley essential oil. In some embodiments, each such oil is present in a concentration of 0.05% to 0.5%, for example about 0.2%. The inclusion of one or more such essential oils may provide additional optional adjunct components within the formulation and may assist in tailoring the composition to a desired topical profile.

[0033] The composition may further comprise one or more additional extracts. In some embodiments, white willow bark extract is present in a concentration of 0.05% to 0.3%, for example about 0.14%. In some embodiments, cayenne extract is present in a concentration of 0.05% to 0.3%, for example about 0.14%. In some embodiments, calendula extract is present in a concentration of 0.001 % to 0.05%, for example about 0.01%. These ingredients may be incorporated as optional adjuncts within the formulation and may contribute to the overall topical properties of the composition.

[0034] The formulation may be provided as a semisolid topical preparation, for example as a salve. In particular embodiments, the formulation is configured as a rollon salve. Such a format may provide a convenient and controlled means of applying the composition directly to an affected area, may assist in reducing wastage, and maysupport repeated local application over joints affected by rheumatoid arthritis. In some embodiments, the formulation is free of artificial preservatives or synthetic additives, which may improve suitability for users seeking a more natural topical preparation or for users with sensitive skin.

[0035] In use, the composition may be applied directly to clean, dry skin over affected joints or other areas of inflammation associated with rheumatoid arthritis. In some embodiments, the composition is applied at least twice daily, although other application regimens may be adopted as appropriate. The composition may be gently spread or massaged over the target area following application. By applying the composition directly to the affected region, the method may provide localised relief in a practical and user-friendly manner.

[0036] The semisolid carrier system may assist in maintaining the active ingredient at the application site for a period sufficient to promote dermal uptake and local tissue exposure. The combination of coconut oil, beeswax, cocoa butter, and menthol may provide a composition that is readily applied, remains localised to the target region, and supports delivery of CBD to tissues associated with affected joints. The composition may thereby provide targeted relief of one or more symptoms associated with rheumatoid arthritis in a non-invasive manner. The method and composition may accordingly provide an effective and convenient approach for relieving symptoms associated with rheumatoid arthritis. By delivering cannabidiol locally in a semisolid topical formulation, the composition may address limitations associated with conventional systemic treatments and may provide a practical option for ongoing symptom management.Patient studies

[0037] The effectiveness of the present topical cannabidiol salve for relieving one or more symptoms associated with rheumatoid arthritis has been assessed through patient case studies, with patient feedback indicating improvements in pain relief, reduction in inflammation, and enhanced mobility following topical use of the composition.

[0038] A first patient, a 58-year-old female with a history of rheumatoid arthritis spanning more than ten years, reported substantial improvement after using the present CBD salve consistently over an eight-month period, including regular day and night application. Prior to use of the salve, her treatment regimen included Plaquenil, Mobic, Endone, and Rituximab infusions, with only limited control of symptoms. Following incorporation of the salve into her management routine, she reported being able to cease painkillers and anti-inflammatory medication. She further reported that joint swelling and tenderness had reduced significantly, particularly in her hands, with corresponding improvement in mobility and reduced reliance on compression gloves. Inflammatory markers were also reported to improve, with erythrocyte sedimentation rate (ESR) decreasing from 25 to 2 and C-reactive protein (CRP) falling below detectable levels. The patient noted that the salve could be applied directly to specific areas of discomfort and found this targeted mode of use to be particularly beneficial.

[0039] A second patient, a 67-year-old female with rheumatoid arthritis and osteoarthritis affecting her knees, hips, and feet, reported substantial benefit after approximately three months of use. Prior to treatment, she experienced considerable mobility difficulties and relied on external support during outings. Following morning and evening application of the salve, she reported a marked reduction in pain across the affected joints, allowing freer movement and reduced reliance on walking aids. She also indicated that she had been able to reduce her dependence on prescribed pain medication and considered the salve to have materially improved her quality of life.

[0040] A third patient, a 69-year-old female with rheumatoid arthritis and fibromyalgia, reported feedback after approximately four weeks of using the salve. The patient had experienced widespread chronic pain, muscle tenderness, and disrupted sleep. Following topical application of the salve to affected regions, including the hips and arms, she reported rapid and sustained relief, with reduction in pain intensity and improved sleep quality. The patient further indicated that use of the salve enabled a reduction in intake of Panadol, Nurofen, and sleeping tablets. She expressed satisfaction with the salve as a targeted topical composition for symptom relief.

[0041] A fourth patient, a 62-year-old male with a 23-year history of rheumatoid arthritis, reported significant benefit after using the salve multiple times daily for approximately eight weeks. Prior to use, chronic joint inflammation, particularly in the hands and feet, had adversely affected both mobility and sleep quality. The patient reported that topical use of the salve reduced inflammation and swelling in the affected joints and provided sufficient relief during flare-ups to avoid the need for stronger painkillers such as Endone. He also indicated that the salve assisted him in managing pain without adding further systemic medication such as Nurofen or Panadol, and identified the composition as a useful ongoing component of his symptom-management routine.

[0042] These case studies indicate that the present topical CBD salve may provide a practical and effective means for localised relief of symptoms associated with rheumatoid arthritis. In particular, the salve may assist in reducing pain, swelling, tenderness, and mobility impairment, while also offering a targeted topical alternative that may reduce reliance on systemic medication in some users.Preferred embodiment

[0043] According to one embodiment, the formulation comprises the following active ingredient and excipients with their respective percentages shown:Exemplary Method of preparation

[0044] The topical cannabidiol salve for relieving one or more symptoms associated with rheumatoid arthritis may be prepared by a method configured to provide a substantially homogeneous and stable semisolid composition suitable for topical administration. The method may commence with selection of cannabidiol, for example pharmaceutical-grade cannabidiol, which may be weighed to provide a desired concentration in the final formulation. In some embodiments, the cannabidiol is present in the final composition in an amount of 30 mg / g to 60 mg / g, for example about 46 mg / g.

[0045] A carrier system comprising coconut oil, beeswax, and cocoa butter may be prepared in a heated mixing vessel, such as a jacketed stainless-steel vessel. In some embodiments, coconut oil is first introduced and heated to a temperature sufficient to liquefy the oil, for example about 50°C to 60°C. Beeswax may then be added and melted under stirring, followed by addition of cocoa butter. The mixture may be maintained under controlled heating and agitation until the carrier components form a substantially uniform blend. In some embodiments, the coconut oil is present in an amount of 8% to 15%, for example about 10.9%, the beeswax is present in an amount of 25% to 40%, for example about 33%, and the cocoa butter is present in an amount of 20% to 35%, for example about 27.7%. The resulting carrier phase may provide a semisolid matrix suitable for retaining the active ingredient at the site of application and for facilitating convenient topical use.

[0046] Once the carrier system has reached a substantially uniform consistency, the cannabidiol may be added gradually while the temperature is maintained and the mixture is continuously agitated. Agitation may be continued for a period sufficient to promote uniform dispersion or solubilisation of the cannabidiol within the carrier phase, for example for about 20 to 30 minutes. This may assist in achieving a consistent formulation and reducing variation in active ingredient distribution throughout the batch.

[0047] Menthol may then be incorporated into the mixture. In some embodiments, menthol is added in crystalline form and allowed to dissolve under maintained temperature and agitation to provide a substantially uniform composition. The menthol may be present in an amount of 15% to 25%, for example about 21%. Incorporation of menthol in this manner may assist in producing a composition that supports dermal delivery of cannabidiol and provides a cooling sensation upon application.

[0048] One or more optional oils or extracts may be incorporated after addition of the menthol. In some embodiments, lavender essential oil is present in an amount of 0.05% to 0.5%, for example about 0.2%, ginger essential oil is present in an amount of 0.05% to 0.5%, for example about 0.2%, and arnica extract is present in an amount of 0.05% to 0.3%, for example about 0.1%. In some embodiments, one or more Tasmanian essential oils are additionally or alternatively included, such as Rosalina oil, rosemary oil, kunzea oil, peppermint oil, and / or parsley essential oil, each optionally being present in an amount of 0.05% to 0.5%, for example about 0.2%. Additional adjunct ingredients, such as white willow bark extract and cayenne extract, may each be present in an amount of 0.05% to 0.3%, for example about 0.14%, and calendula extract may be present in an amount of 0.001% to 0.05%, for example about 0.01%. In some embodiments, these optional ingredients are added after formation of the carrier phase and incorporation of the cannabidiol, which may reduce prolonged heat exposure and assist in maintaining the integrity of heat-sensitive constituents.

[0049] After the ingredients have been combined, the mixture may be cooled under controlled conditions, optionally with continued stirring, to maintain uniformity and reduce or inhibit separation of components. As the temperature decreases, for example below about 40°C, the composition may progressively assume a semisolid consistency suitable for topical application. Controlled cooling may assist in preserving formulation uniformity and in producing a salve having a desired consistency, spreadability, and stability.

[0050] The resulting composition may be dispensed while still flowable into presterilised containers, such as roll-on applicator containers or other dispensing units, and then sealed to reduce contamination. The filled containers may be stored under suitable conditions, for example at room temperature and away from direct sunlight. Quality control measures may include visual inspection, homogeneity assessment, and stability testing to confirm batch consistency and product suitability.

[0051] This method of preparation may provide a topical composition having a stable semisolid carrier phase, substantially uniform distribution of cannabidiol, and a consistency suited to convenient local application over affected joints or areas of inflammation. The resulting formulation may thereby provide a practical product for repeated topical use in relieving one or more symptoms associated with rheumatoid arthritis.

[0052] The described arrangement may provide a number of technical advantages and effects arising from the combination of cannabidiol with the specified semisolid carrier system and menthol. In particular, the carrier system comprising coconut oil, beeswax, and cocoa butter may provide a semisolid dermal matrix that supports incorporation of the cannabidiol, facilitates spreading over the skin surface, and assists in retaining the composition at the site of application. This may improve local residence of the active ingredient relative to less viscous topical preparations.

[0053] The inclusion of menthol may further assist dermal delivery of the cannabidiol and may increase availability of the active ingredient in tissues underlying the application site. The claimed arrangement may thereby support localised exposure of cannabidiol in tissues associated with affected joints or areas of inflammation. Thesemisolid form may also improve ease and precision of topical administration where the composition is applied directly to selected joints.

[0054] Where optional oils or extracts are included, these may provide additional adjunct components without altering the underlying semisolid carrier architecture. The claimed composition and method may therefore provide a technically practical topical system for repeated local application, with reduced reliance on systemic administration in order to achieve relief of one or more symptoms associated with rheumatoid arthritis.

[0055] The foregoing description, for purposes of explanation, used specific nomenclature to provide a thorough understanding of the invention. However, it will be apparent to one skilled in the art that specific details are not required in order to practise the invention. Thus, the foregoing descriptions of specific embodiments of the invention are presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed as obviously many modifications and variations are possible in view of the above teachings. The embodiments were chosen and described in order to best explain the principles of the invention and its practical applications, thereby enabling others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is intended that the following claims and their equivalents define the scope of the invention.

Claims

Claims1. A method of relieving one or more symptoms associated with rheumatoid arthritis, comprising topically applying a composition comprising:(a) cannabidiol;(b) a carrier system comprising:(i) coconut oil;(ii) beeswax; and(iii) cocoa butter; and(c) menthol.

2. The method of claim 1, wherein the cannabidiol is present in a concentration of 30 mg / g to 60 mg / g.The method of claim 1, wherein the coconut oil is present in a concentration of 8%4. The method of claim 1, wherein the beeswax is present in a concentration of 25% to 40%.

5. The method of claim 1, wherein the cocoa butter is present in a concentration of 20% to 35%.

6. The method of claim 1, wherein the menthol is present in a concentration of 15% to 25%.

7. The method of claim 1, further comprising lavender essential oil in a concentration of 0.05% to 0.5%.

8. The method of claim 1, further comprising ginger essential oil in a concentration of 0.05% to 0.5%.

9. The method of claim 1, further comprising arnica extract in a concentration of 0.05% to 0.3%.

10. The method of claim 1, wherein the composition further comprises one or more Tasmanian essential oils selected from the group consisting of:(a) Tasmanian Rosalina essential oil in a concentration of 0.05% to 0.5%;(b) Tasmanian rosemary essential oil in a concentration of 0.05% to 0.5%;(c) Tasmanian kunzea essential oil in a concentration of 0.05% to 0.5%; and (d) Tasmanian peppermint essential oil in a concentration of 0.05% to 0.5%.

11. The method of claim 10, wherein the composition includes Tasmanian parsley essential oil in a concentration of 0.05% to 0.5%.

12. The method of claim 1, further comprising white willow bark extract in a concentration of 0.05% to 0.3%.

13. The method of claim 1, further comprising cayenne extract in a concentration of 0.05% to 0.3%.

14. The method of claim 1, further comprising calendula extract in a concentration of 0.001% to 0.05%.

15. The method of claim 1, wherein the composition is applied directly to affected joints.

16. The method of claim 15, wherein the composition is applied to the affected joints at least twice daily.

17. The method of claim 15, wherein the composition is applied to the affected joints as a roll-on salve.

18. The method of claim 1, wherein the formulation is free of artificial preservatives or synthetic additives.

19. A topical composition comprising:(a) cannabidiol;(b) a carrier system comprising:(i) coconut oil;(ii) beeswax; and(iii) cocoa butter; and(c) menthol,wherein the composition is for relieving one or more symptoms associated with rheumatoid arthritis.

20. The composition of claim 19, wherein the cannabidiol is present in a concentration of 30 mg / g to 60 mg / g.

21. The composition of claim 19, wherein the coconut oil is present in a concentration of 8% to 15%.

22. The composition of claim 19, wherein the beeswax is present in a concentration of 25% to 40%.

23. The composition of claim 19, wherein the cocoa butter is present in a concentration of 20% to 35%.

24. The composition of claim 19, wherein the menthol is present in a concentration of 15% to 25%.

25. The composition of claim 19, further comprising one or more essential oils selected from the group consisting of:(a) lavender essential oil in a concentration of 0.05% to 0.5%;(b) ginger essential oil in a concentration of 0.05% to 0.5%;(c) arnica extract in a concentration of 0.05% to 0.3%; and(d) Tasmanian Rosalina essential oil in a concentration of 0.05% to 0.5%.

26. The composition of claim 19, wherein the composition further comprises Tasmanian rosemary essential oil in a concentration of 0.05% to 0.5%.

27. The composition of claim 19, wherein the composition further comprises Tasmanian kunzea essential oil in a concentration of 0.05% to 0.5%.

28. The composition of claim 19, wherein the composition further comprises Tasmanian peppermint essential oil in a concentration of 0.05% to 0.5%.

29. The composition of claim 19, further comprising white willow bark extract in a concentration of 0.05% to 0.3%.

30. The composition of claim 19, wherein the composition further comprises cayenne extract in a concentration of 0.05% to 0.3%.

31. The composition of claim 19, wherein the composition further comprises calendula extract in a concentration of 0.001% to 0.05%.

32. The composition of claim 19, wherein the composition is formulated as a roll-on salve.

33. The composition of claim 19, wherein the formulation is free of artificial preservatives or synthetic additives.

Images